We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Yeast-Based COVID-19 Diagnostic Test Could Detect SARS-CoV-2 in Saliva Faster Than RT-PCR

By LabMedica International staff writers
Posted on 01 Feb 2021
A rapid COVID-19 diagnostic test based on a reaction between yeast and the novel coronavirus, will rapidly detect the presence of SARS-CoV-2 in saliva and will be available by mid-2021.

The yeast-based COVID-19 diagnostic test being developed by BIOinFOOD (São Paulo, Brazil) uses a biosensor consisting of a genetically modified brewer's yeast (Saccharomyces cerevisiae), which changes color if human ACE2 receptor expressed by the yeast's membrane binds to the spike glycoprotein present on the external surface of the virus.

The innovation involved in the COVID-19 diagnostic test came out of a technology mastered previously by BIOinFOOD. More...
The firm offers a biotech platform based on S. cerevisiae, a versatile microorganism widely used in industry as a biofactory. Organic acids, amino acids, enzymes, and therapeutic proteins are some of the outputs of the platform. The firm also develops custom yeasts for use by bakeries and breweries to suit consumer tastes.

According to the researchers' expectations, the new test will be both fast and cheaper than RT-PCR because of the low cost of yeast, the main input. Another important difference is that it will probably use saliva. Being non-invasive is an advantage for diagnostic tests. Many people experience intense discomfort when undergoing collection of their material by nasal swab. Additionally, the sensitivity of the test is expected to be high, meaning it will be able to detect the virus only a few days after infection. Once the working hypothesis has been fully validated, the scientists expect the test to be brought to market and freely available for purchase during first-half 2021. The raw materials for the product are simple and distribution of the diagnostic test should be logistically straightforward.

"The yeast is normally beige. When this interaction takes place, the presence of the virus is signaled by a fluorescent green that can easily be detected by the equipment typically found in clinical analysis labs," said Gleidson Silva Teixeira, one of BIOinFOOD's partners. "We plan eventually to have the yeast emit red light, which will be easier to identify. In this case, anyone will be perfectly capable of using the test, even at home."

Related Links:
BIOinFOOD


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new RABTA sets a high standard in laboratory diagnostics (Photo courtesy of Randox)

Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics

A state-of-the-art analyzer combines advanced technology with exceptional efficiency to meet the demanding needs of modern laboratories. Randox Toxicology (Antrim, Ireland) has launched its pioneering... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.